In women, hormone therapy is a risk factor for venous thrombosis, a blood clot forming deep inside the vein. Despite the fact that the disorder is rare, it increases exponentially during menopause and can be deadly. The hormone trials conducted thus far, focusing on proteins in blood coagulation, have not yet led to a risk profile, thereby precluding identification of women at risk.

Treatment with chemotherapy and bevacizumab, an anticancer drug, is associated with a greater risk of blood clots in patients’ arteries compared with treatment with chemotherapy only, according to a study published online August 7 in the Journal of the National Cancer Institute.

Venous thrombosis (VTE), the formation of blood clots in a vein, is a major health problem for hospitalized patients in the United States. In the short term, VTE can lead to deep vein thrombosis (DVT), typically in the legs, and pulmonary embolism (PE), which occurs when a piece of the blood clot migrates into an artery of the lungs.

A novel method to prevent hemorrhagic complications of thrombolytic therapy of blood clots is discovered.

The United Nations World Health Organization (WHO) released results from a research project warning that the risk of developing fatal blood clots during travel doubles after the passenger has been seated for four hours or more.

The World Health Organization’s (WHO) studies’ results showed that one in 6,000 passengers, who travel during four or more hours has a risk of acquiring deep vein thrombosis.

Up to 25,000 people may die needlessly each year due to the failure to prevent blood clots known as venous thromboembolisms (VTE) in UK hospitals, say experts in this week's BMJ.